Genotype-Guided Strategy for P2Y12 Inhibitors in Coronary Artery Disease: A Meta-Analysis of Randomized Clinical Trials

JACC Cardiovasc Interv. 2020 Mar 9;13(5):659-661. doi: 10.1016/j.jcin.2019.11.019.
No abstract available

Publication types

  • Letter
  • Meta-Analysis

MeSH terms

  • Aged
  • Clinical Decision Rules*
  • Clinical Decision-Making
  • Coronary Artery Disease / diagnostic imaging
  • Coronary Artery Disease / therapy*
  • Cytochrome P-450 CYP2C19 / genetics*
  • Cytochrome P-450 CYP2C19 / metabolism
  • Female
  • Humans
  • Male
  • Middle Aged
  • Percutaneous Coronary Intervention* / adverse effects
  • Percutaneous Coronary Intervention* / instrumentation
  • Pharmacogenomic Variants*
  • Platelet Aggregation Inhibitors / administration & dosage*
  • Platelet Aggregation Inhibitors / adverse effects
  • Platelet Aggregation Inhibitors / pharmacokinetics
  • Precision Medicine*
  • Predictive Value of Tests
  • Purinergic P2Y Receptor Antagonists / administration & dosage*
  • Purinergic P2Y Receptor Antagonists / adverse effects
  • Purinergic P2Y Receptor Antagonists / pharmacokinetics
  • Randomized Controlled Trials as Topic
  • Risk Assessment
  • Risk Factors
  • Stents
  • Treatment Outcome

Substances

  • Platelet Aggregation Inhibitors
  • Purinergic P2Y Receptor Antagonists
  • CYP2C19 protein, human
  • Cytochrome P-450 CYP2C19